Current Headlines

  1. argenx Awarded €2.5M VLAIO Grant To Identify Novel Therapeutic Antibodies

    argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has received a €2.5 million grant from Flanders Innovation and Entrepreneurship (VLAIO)

  2. Astex Continues To Deliver In Oncology As Erdafitinib, A Potential New Treatment For Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation

    Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced recently that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer

  3. Exelixis Submits U.S. Supplemental New Drug Application For CABOMETYX (Cabozantinib) For Previously Treated Advanced Hepatocellular Carcinoma

    Exelixis, Inc. recently announced it has completed the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CABOMETYX (cabozantinib) tablets as a treatment for patients with previously treated advanced hepatocellular carcinoma (HCC)

  4. CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials

    CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has selected four new, investigational LADR™ (Linker Activated Drug Release) candidates for advancement toward clinical testing in cancer patients

  5. Zymeworks Advances Clinical Candidate Incorporating Technology From Kairos Acquisition

    Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, recently announced that ZW49 is the first product candidate selected for clinical development utilizing the ZymeLink antibody-drug conjugate (ADC) platform, acquired as part of the Company’s 2016 acquisition of Kairos Therapeutics

  6. Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate For Development

    Bridge Medicines and the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) announced today the acceptance into Bridge Medicines of its first drug candidate, a small molecule for the treatment of basal cell carcinoma, that originated in the laboratory of Rockefeller University's Dr. Tarun Kapoor and successfully completed pre-clinical trials at Tri-I TDI

  7. CrownBio Enters Strategic Partnership With Phanes Therapeutics To Accelerate Discovery And Development Of Phanes’ Novel Oncology Agents

    Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline

  8. Sosei Regains Worldwide Rights From Teva To Develop And Commercialize Novel Small Molecule CGRP Antagonists For Migraine And Other Severe Headaches

    Sosei Group (“Sosei” or the “Company”; TOKYO Mothers Index: 4565), the world leader in GPCR medicine design and development, announced that it has regained worldwide rights from Teva Pharmaceutical Industries Ltd. (“Teva”) to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches

  9. Poxel Announces Initiation Of TIMES 2 And TIMES 3 Trials For The Phase 3 Program For Imeglimin, An Investigational Therapeutic Agent For Type 2 Diabetes, In Japan

    POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today the initiation of the TIMES 2 and TIMES 3 trials for the Phase 3 program for Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan

  10. Alnylam Retains Global Rights To Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

    Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced recently that Sanofi Genzyme has declined its opt-in for the development and commercialization of lumasiran (ALN-GO1), an investigational RNAi therapeutic for the treatment of Primary Hyperoxaluria Type 1 (PH1)